Dapagliflozin-induced abnormal uterine bleeding in a patient with dilated cardiomyopathy and chronic heart failure: a case report.
J Int Med Res
; 52(8): 3000605241271750, 2024 Aug.
Article
in En
| MEDLINE
| ID: mdl-39180294
ABSTRACT
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are extensively used in the management of heart failure because of their cardiovascular benefits. Adverse drug reactions associated with dapagliflozin include diabetic ketoacidosis, fungal infections, and increased blood glucose concentrations. However, abnormal uterine bleeding is not a known side effect of dapagliflozin. We report a 75-year-old Chinese woman with dilated cardiomyopathy and chronic heart failure who experienced abnormal uterine bleeding while taking dapagliflozin. Notably, cessation of dapagliflozin administration resulted in the disappearance of uterine bleeding. These findings suggest that dapagliflozin possesses additional potential mechanisms, but these mechanisms require further investigation. Furthermore, healthcare professionals should remain vigilant regarding the occurrence of uterine bleeding when prescribing dapagliflozin.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Uterine Hemorrhage
/
Benzhydryl Compounds
/
Cardiomyopathy, Dilated
/
Sodium-Glucose Transporter 2 Inhibitors
/
Glucosides
/
Heart Failure
Limits:
Aged
/
Female
/
Humans
Language:
En
Journal:
J Int Med Res
/
J. int. med. res
/
Journal of international medical research
Year:
2024
Document type:
Article
Affiliation country:
China
Country of publication:
United kingdom